Real World Evidence

PLAINSBORO, N.J. – November 07, 2026 -- Novo Nordisk reported that adults with metabolic dysfunction-associated steatohepatitis (MASH) who started semaglutide 2.4 mg once weekly lost a statistically significant mean 18.9 lb (8.6 kg; about 8%) from baseline versus patients on resmetirom at six months, according to real-world data presented at AASLD The Liver Meeting 2026 in Denver.

PLATINUM-Truveta compares 2,873 semaglutide patients with 2,285 on resmetirom

The retrospective cohort study drew on de-identified electronic medical records from 30 US health systems in the Truveta database, covering June 2021 through March 2026. Semaglutide 2.4 mg was also associated with significantly greater reductions than resmetirom in AST and some cardiometabolic measures. Researchers assessed ALT, AST, body weight, HbA1c, platelets, triglycerides, HDL and LDL at three and six months.

Laval – November 06, 2026 -- Only 62.0% of patients hospitalized with severe alcohol-associated hepatitis (AH) in the United States were estimated to survive 12 months, according to a real-world study from Bausch Health Companies Inc. and its gastroenterology unit, Salix Pharmaceuticals.

Study of 1,630 US adults tracks rehospitalization and transplant rates

The companies are presenting the poster, "Clinical Burden and Outcomes in a Large Real-World Cohort of Patients Hospitalized with Severe Alcohol-Associated Hepatitis," at the American Association for the Study of Liver Diseases' The Liver Meeting 2026. The meeting runs November 5-9 in Denver, Colorado. The cohort comprised 1,630 adults.

Rehospitalization climbs from 31.4% at 30 days to 69.1% at 12 months

Within 30 days of discharge, 31.4% of patients were rehospitalized. The estimated rate reached 69.1% by 12 months. The estimated liver transplantation rate at 12 months was 8.5%.

THOUSAND OAKS – November 06, 2026 -- Amgen reported that Repatha (evolocumab) lowered the risk of fatal or nonfatal heart attack by 20% compared with ezetimibe in adults with atherosclerotic cardiovascular disease (ASCVD) and prior statin use. The real-world study followed 544,103 patients for up to four years and was published in The American Journal of Preventive Cardiology.

Four-year heart attack risk falls to 5.88% with Repatha versus 7.76% with ezetimibe

Among 225,048 patients with a baseline LDL-C measurement, the four-year cumulative risk of heart attack was 5.88% on Repatha and 7.76% on ezetimibe. Among patients without a baseline LDL-C measurement, the corresponding risks were 5.65% and 7.06%.

The primary outcome was fatal or nonfatal myocardial infarction. The hazard ratio was 0.80 (95% CI, 0.70-0.91).

TOKYO – November 03, 2026 -- Japan's market for EMR-derived healthcare data is projected to grow from about ¥3.9 billion in 2025 to about ¥25 billion in 2035, according to a whitepaper from TXP Medical Co., Ltd. The report, "The State of Japanese Real-World Evidence," targets pharmaceutical Medical Affairs departments. It is the first publication from the company's relaunched "Medical Data Lab" media unit.

EMR data share to rise from 11% to 29% of Japan's secondary-use market

The overall market for secondary use of healthcare data is forecast to grow from about ¥35 billion in 2025 to about ¥85 billion in 2035. EMR-derived data is expected to climb from 11% of that market to 29% over the period.

Stockholm – October 30, 2026 -- Eisai will present five years of Clarity AD data on lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, November 16-19, 2026, according to its partner BioArctic AB (Nasdaq Stockholm: BIOA B). The dataset spans the core and long-term extension phases and is one of the longest follow-up sets reported to date for an approved anti-amyloid Alzheimer's therapy.

LEADER study tests lecanemab in US clinical practice three years after approval

A symposium on Wednesday, November 18, 11:00-11:40 AM ET, will cover the retrospective, multicenter LEADER study. The study draws on real-world data from different types of US treatment centers, three years after FDA approval.

Three analyses are scheduled: utilization and outcomes from initiation through maintenance therapy, sex-based outcomes, and at-home subcutaneous administration.

Europe – October 27, 2026 -- Continuous glucose monitoring (CGM) was associated with a 45% lower risk of death at one year among adults with type 2 diabetes on basal insulin, according to a study presented at the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting.

The analysis used Truveta Data to track nearly 28,000 adults with type 2 diabetes receiving basal insulin therapy. Researchers combined longitudinal electronic health record (EHR) and mortality data in a target trial emulation that compared CGM users with non-users.

CGM users show 36% lower two-year mortality risk

At one year, CGM users had a 45% lower risk of death from any cause than non-users. At two years, the reduction was 36%.

Bad Homburg, Germany – October 19, 2026 -- Fresenius Medical Care reports that 74% of more than 10,000 high-volume hemodiafiltration (HvHDF) treatments delivered on its 5008X CAREsystem in the United States reached the target convective dose of 23 liters or greater. The company will present the data at the American Society of Nephrology's Kidney Week 2026, held October 21-25 in Denver, Colorado.

U.S. real-world data shows HvHDF delivery matches European targets

The company says the findings show HvHDF can be delivered in routine U.S. clinical practice with treatment targets comparable to those reported in Europe. Fresenius researchers are studying U.S. implementation as adoption expands. The work feeds the company's BEACON-US research initiative, which examines online HDF therapy and patient outcomes in the U.S.

North Chicago – October 17, 2026 -- AbbVie (NYSE: ABBV) is presenting 20 new scientific abstracts from its inflammatory bowel disease (IBD) portfolio at the 2026 United European Gastroenterology (UEG) Week, held October 17-20 in Barcelona, Spain. The data cover long-term and real-world outcomes for Skyrizi (risankizumab) and Rinvoq (upadacitinib) in Crohn's disease (CD) and ulcerative colitis (UC).

Risankizumab maintains remission in UC through week 96

In the COMMAND study, patients on risankizumab 180 mg reached as-observed clinical remission rates of 54.0%-73.1% at week 96. Endoscopic remission rates were 38.8%-53.5%. The ranges span advanced therapy-naïve and advanced therapy-experienced patients, and the study reports up to three years of maintenance treatment.

Paris – October 15, 2026 -- The share of patients reporting sleep difficulties fell by 59%, 56% and 55% within 48 hours of starting Mucosolvan or Bisolvon, according to a new real-world study from Opella on acute chesty cough.

Sleep complaints drop across three categories within 48 hours

The percentage of patients reporting difficulty falling asleep fell by 59%. Those reporting difficulty staying asleep fell by 56%, and those reporting sleep-related tiredness by 55%. Opella describes sleep disruption as a primary patient concern.

Social impact of cough improves meaningfully within 72 hours

Patients achieved a clinically meaningful improvement in the social impact of cough within 72 hours. Data also showed improvements in daily functioning from the first day of treatment.

New York – September 30, 2026 -- Direct-to-patient healthcare company Ro presented the first real-world evidence on Novo Nordisk's oral Wegovy pill at the EASD2026 meeting in Milan on September 30, based on outcomes from patients on its platform who switched from an injectable GLP-1.

Ro's platform generates first clinical data on Wegovy pill switch patients

The short oral session study, co-authored by Ro clinical advisors Dr. Beverly Tchang and Dr. Louis Aronne, tracked patients with overweight or obesity who transitioned from an injectable GLP-1 and remained persistent with the Wegovy pill for three months on Ro's platform.